MedPath

Ovarian Reserve Following Bilateral Salpingectomy Versus Tubal Ligation During Cesarean Section

Not Applicable
Conditions
Ovarian Reserve
Interventions
Procedure: Tubal ligation
Procedure: Bilateral salpingectomy
Registration Number
NCT02377128
Lead Sponsor
Wolfson Medical Center
Brief Summary

The aforementioned study was designed to evaluate short term ovarian reserve as assessed by anti-Mullerian hormone(AMH) levels following bilateral salpingectomy versus tubal ligation, as part of cesarean sections performed in women requesting future sterilization. The investigators aim to recruit 3 groups of 15 women undergoing elective cesarean section at the investigators' institution, 2 of which request sterilization (allocated to tubal ligation or bilateral salpingectomy) and one undergoing solely cesarean section. The groups will have blood drawn for AMH prior to the procedure and at a post-operation visit 8 weeks following. This is preformed in light of validated data offering better sterilization and possible diminished future risk of ovarian cancer with salpingectomy. Also, is has been proved to be just as safe as tubal ligation. This will be performed as a randomized controlled trial.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
45
Inclusion Criteria
  • Women undergoing elective cesrean section at the investigators' institution, requesting sterilization, willing to have blood withdrawn for AMH levels prior to surgery, willing to participate in 8 weeks post-operation follow up with blood withdrawn
Exclusion Criteria
  • Non-elective cesarean section, non willing to have blood withdrawn or participate in follow up, prior salpingectomy, prior premature ovarian failure/egg donation

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Tubal ligationTubal ligationCesarean section with tubal ligation
Bilateral salpingectomyBilateral salpingectomyCesarean section with bilateral salpingectomy
Primary Outcome Measures
NameTimeMethod
Change from baseline in Anti Mullerian hormone (AMH) levels ng/mL at 8 weeksBaseline and 8 weeks following surgery

AMH levels

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath